在本周的医疗健康领域，一系列的政策、市场动态与企业事件共同绘就了一幅生动的行业画卷。其中，最为引人注目的莫过于射频美容仪新规的延期执行与鱼腥草芩蓝合剂转为非处方药的政策调整。自2021年1月起实施的射频美容仪相关管理规定，原计划于今年1月正式执行，但鉴于市场反馈与行业发展的复杂性，这一规定将延期两年执行，为行业提供了更为宽松的发展环境。与此同时，鱼腥草芩蓝合剂作为传统中药制剂，其管理政策的调整使其转为非处方药，有望提升其市场可及性与使用便利性，满足更多患者的健康需求。
在投融资与资本市场动态方面，本周共有9家医疗健康领域的企业获得了资本的青睐，融资总额达到数亿元人民币，显示出资本对医疗健康领域持续的热忱与信心。其中，线上慢病管理平台方舟云康成功上市，标志着其在互联网医疗领域的领先地位与市场潜力得到了资本市场的高度认可。
在企业上市与IPO方面，科创板的“首富”企业选择赴港进行二次上市，这一举措不仅体现了企业全球化战略的深化，也反映了其在国际资本市场寻求更广泛融资与合作机会的决心。此外，先声药业的抗新冠药“先诺欣”获得国家药监局的常规批准，这一批准不仅加速了抗新冠药物的市场供应，也为全球疫情防控贡献了中国力量。
在业绩与市场表现方面，东阿阿胶预计其净利润将增长三成，这不仅体现了传统中医药品牌在市场中的强劲竞争力，也预示着中医药市场正迎来新的增长点。这些动态共同展示了医疗健康领域在政策调整、资本运作、企业创新与市场表现方面的活力与潜力，为行业的未来发展注入了积极的信号。
英语如下：
News Title: “Weekly Health and Medical Dynamics: Regulation Extension, Pharma Financing and Investments, New Drug Approvals”
Keywords: Delayed RF Beauty Device Regulation, Fish Grass and Scutellaria Compound Switch to Over-the-Counter, Dong’e Arsenic Elk Antler Revenue Growth
News Content: This week, a vivid picture of the health and medical industry was painted by a series of policies, market dynamics, and corporate events. Among the highlights, the extension of the implementation of the regulation on RF beauty devices and the policy adjustment for the over-the-counter status of the traditional Chinese medicine formula, Fish Grass and Scutellaria Compound, attracted the most attention. The regulation, which was to take effect from January 2021, has been postponed for two years, providing a more relaxed environment for the industry to develop. At the same time, the policy adjustment for the over-the-counter status of the traditional Chinese medicine formula is expected to increase its market accessibility and convenience, meeting the health needs of more patients.
In terms of financing and capital market dynamics, nine health and medical companies received capital favor, with a total funding of hundreds of millions of RMB, indicating the continuous enthusiasm and confidence of the capital in the health and medical sector. Among them, Fangzhou Cloud Health, a platform for managing chronic diseases online, successfully went public, marking its leading position and market potential in the field of Internet healthcare, which has been recognized by the capital market.
Regarding listings and initial public offerings (IPOs), the “kingpin” enterprise of the Star Market chose to list in Hong Kong for a secondary listing, which not only reflects the deepening of its global strategy but also its determination to seek broader funding and cooperation opportunities in the international capital market. Additionally, Xiansheng Pharmaceutical’s anti-COVID-19 drug, “Xian诺欣”, received regular approval from the National Medical Products Administration, accelerating the market supply of anti-COVID-19 drugs and contributing to global pandemic control efforts.
In terms of performance and market performance, Dong’e Arsenic Elk Antler expects a 30% increase in net profit, reflecting the strong competitive power of traditional Chinese medicine brands in the market and signaling a new growth point in the traditional Chinese medicine market. These dynamics collectively showcase the vitality and potential of the health and medical sector in policy adjustments, capital operations, corporate innovation, and market performance, injecting positive signals for the future development of the industry.
【来源】http://www.chinanews.com/life/2024/07-14/10251300.shtml
Views: 2